Key Takeaways

It’s too soon to tell whether 'liquid biopsy' tests are useful in cancer screening

No controlled studies into the screening benefits of these tests have been completed, even though they’re commercially available

There’s insufficient evidence to show whether the cancers detected by the tests outweigh the harms caused by false positives, researchers argue

TUESDAY, Sept. 16, 2025 (HealthDay News) — “Liquid biopsy” tests using blood samples to screen for multiple types of cancer are attracting much attention, for their potential to catch unseen tumors.

But it's too soon to tell whether they're truly useful in the fight against cancer, a new evidence review warns.

These multicancer early detection (MCD) tests are commercially available as lab-developed blood scans, even thou

See Full Page